1.Research on anti-tumor mechanism of attenuated Salmonella typhimurium VNP20009
Te YIN ; Li-na LIU ; Shi-da DONG ; Bao-lian HUANG ; Chen-yang LI ; Zhi-ting CAO ; Zi-chun HUA
Acta Pharmaceutica Sinica 2023;58(9):2700-2706
Attenuated
2.Ineffectiveness of Skin Tests in Predicting Allergic Reactions Induced by Chinese Herbal Injections.
Chun-Xiao LYU ; Jun-Hua ZHANG ; Bao-He WANG ; Bo-Li ZHANG ; Chang-Xiao LIU ; Yan-Fen LI ; Yu-Hong HUANG
Chinese journal of integrative medicine 2022;28(1):36-42
OBJECTIVE:
To evaluate whether skin tests are suitable to predict the allergy reactions induced by Chinese herbal injections (CHIs).
METHODS:
The skin tests including skin prick tests (SPT), intradermal tests (IDT) and provocation tests including subcutaneous tests and intravenous tests were administered to 249 healthy subjects and 180 allergic patients for 3 CHIs, including ginkgolide injection, diterpene ginkgolide meglumine injection and Salvianolate lyophilized injection. The results of the provocation tests were used as the "gold standard" to determine the sensitivity and specificity of the skin tests.
RESULTS:
The results did not show any significant differences between the healthy and allergy groups in both skin tests and provocation tests (P>0.05). The specificities of SPT and IDT were 0.976 and 0.797, respectively, and the sensitivities of both SPT and IDT were 0.
CONCLUSION
Skin tests are insufficient to predict the likelihood of allergic reactions resulting from CHIs. (ChiCTR-CPC-15006921).
China
;
Humans
;
Hypersensitivity
;
Intradermal Tests
;
Sensitivity and Specificity
;
Skin Tests
3.Comparison of odor and quality of Galli Gigerii Endothelium Corneum derived from domestic chickens and broilers.
Wei HUANG ; Lu-Meng CHEN ; Hao-Zhou HUANG ; Ya-Nan HE ; Xiao-Ming BAO ; Jing YANG ; Jun-Zhi LIN ; Peng TAN ; Li HAN ; Run-Chun XU ; Ding-Kun ZHANG
China Journal of Chinese Materia Medica 2022;47(20):5434-5442
Galli Gigerii Endothelium Corneum(GGEC) is commonly used for the clinical treatment of indigestion, vomiting, diarrhea, and infantile malnutrition with accumulation. In recent decades, omnivorous domestic chickens, the original source of GGEC, has been replaced by broilers, which may lead to significant changes in the quality of the yielding GGEC. Through subjective and objective sensory evaluation, biological evaluation, and chemical analysis, this study compared the odor and quality between GGEC derived from domestic chickens and that from broilers. The odor intensity between them was compared by odor profile analysis and it was found that the fishy odor of GGEC derived from domestic chickens was significantly weaker than that of GGEC from broilers. Headspace-solid phase microextraction-gas chromatography-triple quadrupole tandem mass spectrometry(HS-SPME/GC-QQQ-MS/MS) suggested that the overall odor-causing chemicals were consistent with the fishy odor-causing chemicals. According to the odor activity va-lue and the orthogonal partial least squares discriminant analysis(OPLS-DA) result, dimethyl trisulfide, 2-methoxy-3-isobutylpyrazine, and 2-methylisoborneol were responsible for the fishy odor(OAV≥1) and the content of fishy odor-causing chemicals in GGEC derived from broilers was 1.12-2.13 folds that in GGEC from domestic chickens. The average pepsin potency in GGEC derived from broilers was 15.679 U·mg~(-1), and the corresponding figure for the medicinal from domestic chickens was 26.529 U·mg~(-1). The results of pre-column derivatization reverse-phase high-performance liquid chromatography(RP-HPLC) assay showed that the content of total amino acids and digestion-promoting amino acids in domestic chickens-derived GGEC was 1.12 times and 1.15 times that in GGEC from broilers, and the bitter amino acid content was 1.21 times folds that of the latter. In conclusion, GGEC derived from domestic chickens had weaker fishy odor, stronger enzyme activity, higher content of digestion-promoting amino acids, and stronger bitter taste than GGEC from broilers. This study lays a scientific basis for studying the quality variation of GGEC and provides a method for identifying high-quality GGEC. Therefore, it is of great significance for the development and cultivation of GGEC as both food and medicine and breeding of corresponding varieties.
Animals
;
Odorants/analysis*
;
Chickens
;
Gas Chromatography-Mass Spectrometry/methods*
;
Tandem Mass Spectrometry
;
Solid Phase Microextraction
;
Amino Acids
;
Endothelium/chemistry*
;
Volatile Organic Compounds/analysis*
4.Naoxintong Capsule for Secondary Prevention of Ischemic Stroke: A Multicenter, Randomized, and Placebo-Controlled Trial.
Xiao-Fei YU ; Xu-Ying ZHU ; Can-Xing YUAN ; Dan-Hong WU ; Yu-Wu ZHAO ; Jia-Jun YANG ; Chang-de WANG ; Wei-Wen WU ; Xue-Yuan LIU ; Zhen-Guo LIU ; Zhi-Yu NIE ; Ben-Qiang DENG ; Huan BAO ; Long-Xuan LI ; Chun-Yan WANG ; Hong-Zhi ZHANG ; Jing-Si ZHANG ; Ji-Han HUANG ; Fan GONG ; Ming-Zhe WANG ; Yong-Mei GUO ; Yan SUN ; Ding-Fang CAI
Chinese journal of integrative medicine 2022;28(12):1063-1071
OBJECTIVE:
To examine whether the combination of Naoxintong Capsule with standard care could further reduce the recurrence of ischemic stroke without increasing the risk of severe bleeding.
METHODS:
A total of 23 Chinese medical centers participated in this trial. Adult patients with a history of ischemic stroke were randomly assigned in a 1:1 ratio using a block design to receive either Naoxintong Capsule (1.2 g orally, twice a day) or placebo in addition to standard care. The primary endpoint was recurrence of ischemic stroke within 2 years. Secondary outcomes included myocardial infarction, death due to recurrent ischemic stroke, and all-cause mortality. The safety of drugs was monitored. Results were analyzed using the intention-to-treat principle.
RESULTS:
A total of 2,200 patients were enrolled from March 2015 to March 2016, of whom 143 and 158 in the Naoxintong and placebo groups were lost to follow-up, respectively. Compared with the placebo group, the recurrence rate of ischemic stroke within 2 years was significantly lower in the Naoxintong group [6.5% vs. 9.5%, hazard ratio (HR): 0.665, 95% confidence interval (CI): 0.492-0.899, P=0.008]. The two groups showed no significant differences in the secondary outcomes and safety, including rates of severe hemorrhage, cerebral hemorrhage and subarachnoid hemorrhage (P>0.05).
CONCLUSION
The combination of Naoxintong Capsule with standard care reduced the 2-year stroke recurrence rate in patients with ischemic stroke without increasing the risk of severe hemorrhage in high-risk patients. (Trial registration No. NCT02334969).
Adult
;
Humans
;
Secondary Prevention/methods*
;
Ischemic Stroke
;
Stroke/prevention & control*
;
Cerebral Hemorrhage/complications*
;
Double-Blind Method
;
Platelet Aggregation Inhibitors
5.Mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 regimen in the treatment of pediatric Burkitt lymphoma.
Meng ZHANG ; Pan WU ; Yan Long DUAN ; Ling JIN ; Jing YANG ; Shuang HUANG ; Ying LIU ; Bo HU ; Xiao Wen ZHAI ; Hong Sheng WANG ; Yang FU ; Fu LI ; Xiao Mei YANG ; An Sheng LIU ; Shuang QIN ; Xiao Jun YUAN ; Yu Shuang DONG ; Wei LIU ; Jian Wen ZHOU ; Le Ping ZHANG ; Yue Ping JIA ; Jian WANG ; Li Jun QU ; Yun Peng DAI ; Guo Tao GUAN ; Li Rong SUN ; Jian JIANG ; Rong LIU ; Run Ming JIN ; Zhu Jun WANG ; Xi Ge WANG ; Bao Xi ZHANG ; Kai Lan CHEN ; Shu Quan ZHUANG ; Jing ZHANG ; Chun Ju ZHOU ; Zi Fen GAO ; Min Cui ZHENG ; Yonghong ZHANG
Chinese Journal of Pediatrics 2022;60(10):1011-1018
Objective: To analyze the clinical characteristics of children with Burkitt lymphoma (BL) and to summarize the mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 (CNCL-B-NHL-2017) regimen. Methods: Clinical features of 436 BL patients who were ≤18 years old and treated with the CNCL-B-NHL-2017 regimen from May 2017 to April 2021 were analyzed retrospectively. Clinical characteristics of patients at disease onset were analyzed and the therapeutic effects of patients with different clinical stages and risk groups were compared. Survival analysis was performed by Kaplan-Meier method, and Cox regression was used to identify the prognostic factors. Results: Among 436 patients, there were 368 (84.4%) males and 68 (15.6%) females, the age of disease onset was 6.0 (4.0, 9.0) years old. According to the St. Jude staging system, there were 4 patients (0.9%) with stage Ⅰ, 30 patients (6.9%) with stage Ⅱ, 217 patients (49.8%) with stage Ⅲ, and 185 patients (42.4%) with stage Ⅳ. All patients were stratified into following risk groups: group A (n=1, 0.2%), group B1 (n=46, 10.6%), group B2 (n=19, 4.4%), group C1 (n=285, 65.4%), group C2 (n=85, 19.5%). Sixty-three patients (14.4%) were treated with chemotherapy only and 373 patients (85.6%) were treated with chemotherapy combined with rituximab. Twenty-one patients (4.8%) suffered from progressive disease, 3 patients (0.7%) relapsed, and 13 patients (3.0%) died of treatment-related complications. The follow-up time of all patients was 24.0 (13.0, 35.0) months, the 2-year event free survival (EFS) rate of all patients was (90.9±1.4) %. The 2-year EFS rates of group A, B1, B2, C1 and C2 were 100.0%, 100.0%, (94.7±5.1) %, (90.7±1.7) % and (85.9±4.0) %, respectively. The 2-year EFS rates was higher in group A, B1, and B2 than those in group C1 (χ2=4.16, P=0.041) and group C2 (χ2=7.21, P=0.007). The 2-year EFS rates of the patients treated with chemotherapy alone and those treated with chemotherapy combined with rituximab were (79.3±5.1)% and (92.9±1.4)% (χ2=14.23, P<0.001) respectively. Multivariate analysis showed that stage Ⅳ (including leukemia stage), serum lactate dehydrogenase (LDH)>4-fold normal value, and with residual tumor in the mid-term evaluation were risk factors for poor prognosis (HR=1.38,1.23,8.52,95%CI 1.05-1.82,1.05-1.43,3.96-18.30). Conclusions: The CNCL-B-NHL-2017 regimen show significant effect in the treatment of pediatric BL. The combination of rituximab improve the efficacy further.
Adolescent
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
;
Burkitt Lymphoma/drug therapy*
;
Child
;
Disease-Free Survival
;
Female
;
Humans
;
Lactate Dehydrogenases
;
Lymphoma, B-Cell/drug therapy*
;
Male
;
Prognosis
;
Retrospective Studies
;
Rituximab/therapeutic use*
;
Treatment Outcome
6.Oncomelania hupensis control strategy during the stage moving towards elimination of schistosomiasis in China.
Yi YUAN ; Chun Li CAO ; Xi Bao HUANG ; Qin Ping ZHAO
Chinese Journal of Schistosomiasis Control 2022;34(4):337-340
Oncomelania hupensis is the only intermediate host of Schistosoma japonicum, and O. hupensis control is an important measure for schistosomiasis control. With the progress of national schistosomiasis control program, the prevalence of schistosomiasis is low in China; however, there are still multiple challenges for O. hupensis breeding and schistosomiasis transmission risk. Considering the target of the national schistosomiasis elimination program and environmental protection in the new era, the introduction of precision identification, precision interventions and precision assessment into O. hupensis control may facilitate the progress towards elimination of schistosomiasis in China.
Animals
;
China/epidemiology*
;
Schistosoma japonicum
;
Schistosomiasis/prevention & control*
;
Snails
7.Oncomelania hupensis control strategy during the stage moving towards elimination of schistosomiasis in China
Yi YUAN ; Chun-li CAO ; Xi-bao HUANG ; Qin-ping ZHAO
Chinese Journal of Schistosomiasis Control 2022;34(4):337-340
Oncomelania hupensis is the only intermediate host of Schistosoma japonicum, and O. hupensis control is an important measure for schistosomiasis control. With the progress of national schistosomiasis control program, the prevalence of schistosomiasis is low in China; however, there are still multiple challenges for O. hupensis breeding and schistosomiasis transmission risk. Considering the target of the national schistosomiasis elimination program and environmental protection in the new era, the introduction of precision identification, precision interventions and precision assessment into O. hupensis control may facilitate the progress towards elimination of schistosomiasis in China.
8.Effects of temperature, pH, and H2O2 on the growth and biofilm formation of attenuated Salmonella VNP20009
Jing LI ; Fei-fei BAO ; Jia-huang LI ; Zi-chun HUA
Acta Pharmaceutica Sinica 2021;56(6):1606-1611
Attenuated
9. Apelin-17 Attenuates ER Stress-associated Apoptosis of MPP
Yun-Lu JIANG ; Dan WANG ; Chun-Mei WANG ; Su-Ying LIU ; Jing CHEN ; Bao-Hua CHENG ; Gen-Quan HUANG ; Jing CHEN
Chinese Journal of Biochemistry and Molecular Biology 2021;37(9):1250-1265
Endoplasmic reticulum stress (ERS) is closely related to the development of Parkinson' s disease (PD). Apelin, an endogenous peptide, has a remarkable neuroprotective effect. However, its protective mechanism is still unclear. In the present study, we investigate the molecular mechanism of Apelin-17 reducing the apoptosis of SH-SY5Y cells induced by 1-methyl-4- phenylpyridine (MPP
10.Baseline left ventricular ejection fraction associated with symptom improvements in both children and adolescents with postural tachycardia syndrome under metoprolol therapy.
Yuan-Yuan WANG ; Zhen-Hui HAN ; Yu-Li WANG ; Ying LIAO ; Chun-Yu ZHANG ; Ping LIU ; Chao-Shu TANG ; Jun-Bao DU ; Hong-Fang JIN ; Ya-Qian HUANG
Chinese Medical Journal 2021;134(16):1977-1982
BACKGROUND:
Postural tachycardia syndrome (POTS) is a common childhood disease that seriously affects the patient's physical and mental health. This study aimed to investigate whether pre-treatment baseline left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) values were associated with symptom improvement after metoprolol therapy for children and adolescents with POTS.
METHODS:
This retrospective study evaluated 51 children and adolescents with POTS who received metoprolol therapy at the Peking University First Hospital between November 2010 and July 2019. All patients had completed a standing test or basic head-up tilt test and cardiac echocardiography before treatment. Treatment response was evaluated 3 months after starting metoprolol therapy. The pre-treatment baseline LVEF and LVFS values were evaluated for correlations with decreases in the symptom score after treatment (ΔSS). Multivariable analysis was performed using factors with a P value of <0.100 in the univariate analyses and the demographic characteristics.
RESULTS:
A comparison of responders and non-responders revealed no significant differences in demographic, hemodynamic characteristics, and urine specific gravity (all P > 0.050). However, responders had significantly higher baseline LVEF (71.09% ± 4.44% vs. 67.17% ± 4.88%, t = -2.789, P = 0.008) and LVFS values (40.00 [38.00, 42.00]% vs. 36.79% ± 4.11%, Z = -2.542, P = 0.010) than the non-responders. The baseline LVEF and LVFS were positively correlated with ΔSS (r = 0.378, P = 0.006; r = 0.363, P = 0.009), respectively. Logistic regression analysis revealed that LVEF was independently associated with the response to metoprolol therapy in children and adolescents with POTS (odds ratio: 1.201, 95% confidence interval: 1.039-1.387, P = 0.013).
CONCLUSIONS
Pre-treatment baseline LVEF was associated with symptom improvement after metoprolol treatment for children and adolescents with POTS.
Adolescent
;
Child
;
Humans
;
Metoprolol/therapeutic use*
;
Postural Orthostatic Tachycardia Syndrome/drug therapy*
;
Retrospective Studies
;
Stroke Volume
;
Ventricular Function, Left

Result Analysis
Print
Save
E-mail